Treatment Outcomes of Gemcitabine in Refractory or Recurrent Epithelial Ovarian Cancer Patients |
Chanpanitkitchot, Saranya
(Department of Obstetrics and Gynecology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University)
Tangjitgamol, Siriwan (Department of Obstetrics and Gynecology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University) Khunnarong, Jakkapan (Department of Obstetrics and Gynecology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University) Thavaramara, Thaowalai (Department of Obstetrics and Gynecology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University) Pataradool, Kamol (Department of Obstetrics and Gynecology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University) Srijaipracharoen, Sunamchok (Department of Obstetrics and Gynecology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University) |
1 | Rose PG, Mossbruger K, Fusco N, et al (2003). Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol, 88, 17-21. DOI ScienceOn |
2 | Watanabe Y, Koike E, Nakai H, Etoh T, Hoshiai H (2008). Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer. Int J Clin Oncol, 13, 345-8. DOI ScienceOn |
3 | Yoshino K, Hiramatsu K, Enomoto T, et al (2012). Salvage chemotherapy using gemcitabine for taxane/platinum-resistant recurrent ovarian cancer: a single institutional experience. Anticancer Res, 32, 4029-33. |
4 | Yuan SF, Zhang LP, Zhu LJ, et al (2013). Phase II clinical study on the GEMOX regimen as second- line therapy for advanced ovarian cancer. Asian Pac J Cancer Prev, 14, 3949-53. 과학기술학회마을 DOI ScienceOn |
5 | Poole CJ, Perren T, Gawande S, et al (2006). Optimized sequence of drug administration and schedule leads to improved dose delivery for gemcitabine and paclitaxel in combination: a phase I trial in patients with recurrent ovarian cancer. Int J Gynecol Cancer, 16, 507-14. DOI ScienceOn |
6 | Rose PG (2005). Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma. Int J Gynecol Cancer, 15, 18-22. DOI ScienceOn |
7 | Sehouli J, Stengel D, Oskay G, et al (2002). NOGGO study group. A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy. Ann Oncol, 13, 1749-55. DOI ScienceOn |
8 | Shapiro JD, Millward MJ, Rischin D, et al (1996). Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol, 63, 89-93. DOI ScienceOn |
9 | Su A, Zhang J, Pan ZH, Zhou QM, Lv X (2013). Salvage therapy of gemcitabine plus endostar significantly improves progression-free survival (PFS) with platinum-resistant recurrent epithelial ovarian cancer. Asian Pac J Cancer Prev, 14, 1841-6. 과학기술학회마을 DOI ScienceOn |
10 | Suprasert P, Cheewakriangkrai C, Manopunya M (2012). Outcome of single agent generic gemcitabine in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma. Asian Pac J Cancer Prev, 13, 517-20. 과학기술학회마을 DOI ScienceOn |
11 | Suprasert P, Manopunya M, Cheewakriangkrai C (2014). Outcomes with single agent LIPO-DOX in platinum-resistant ovarian and fallopian tube cancers and primary peritoneal adenocarcinoma - Chiang Mai University Hospital experience. Asian Pac J Cancer Prev, 15, 1145-8. 과학기술학회마을 DOI ScienceOn |
12 | Ferrandina G, Paris I, Ludovisi M, et al (2005). Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival. Gynecol Oncol, 98, 267-73. DOI ScienceOn |
13 | D'Agostino G1, Amant F, Berteloot P, Scambia G, Vergote I (2003). Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. Gynecol Oncol, 88, 266-9. DOI ScienceOn |
14 | Garcia AA, O'Meara A, Bahador A, et al (2004). Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer. Gynecol Oncol, 93, 493-8. DOI ScienceOn |
15 | Ferlay J, Soerjomataram I, Ervik M, et al (2014). GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. |
16 | Ferrandina G, Ludovisi M, Lorusso D, et al (2008). Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol, 26, 890-6. DOI ScienceOn |
17 | Friedlander M, Millward MJ, Bell D, et al (1998). A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol, 12, 1343-5. |
18 | Greggi S, Salerno MG, D'Agostino G, et al (2001). Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer. Oncology, 60, 19-23. DOI ScienceOn |
19 | Pfisterer J, Plante M, Vergote I, et al (2006). Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol, 24, 4699-707. DOI ScienceOn |
20 | Pitakkarnkul S, Tangjitgamol S, Srijaipracharoen S, et al (2013). Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand. Asian Pac J Cancer Prev, 14, 2421-7. 과학기술학회마을 DOI ScienceOn |
21 | Papadimitriou CA, Fountzilas G, Aravantinos G, et al (2004). Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A hellenic cooperative oncology group study. Gynecol Oncol, 92, 152-9. DOI ScienceOn |
22 | Parmar MK, Ledermann JA, Colombo N, et al (2003). Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet, 361, 2099-106. DOI ScienceOn |
23 | Mutch DG, Orlando M, Goss T, et al (2007). Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol, 25, 2811-8. DOI ScienceOn |
24 | Nagourney RA, Brewer CA, Radecki S, et al (2003). Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol, 88, 35-9. DOI ScienceOn |
25 | Ozols RF, Bundy BN, Greer BE, et al (2003). Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol, 21, 3194-200. DOI ScienceOn |
26 | Berek JS, Friedlander M, Hacker NF (2010). Epithelial ovarian, fallopian tube, and peritoneal cancer. In: Berek JS, Friedlander M, Hacker NF (eds) Berek & Hacker's Gynecologic oncology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 484-508. |
27 | Bozas G, Bamias A, Koutsoukou V, et al (2007). Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma. Gynecol Oncol, 104, 580-5. DOI ScienceOn |
28 | Brewer CA, Blessing JA, Nagourney RA, Morgan M, Hanjani P (2006). Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the gynecologic oncology group. Gynecol Oncol, 103, 446-50. DOI ScienceOn |
29 | Khemapech N, Oranratanaphan S, Termrungruanglert W, Lertkhachonsuk R, Vasurattana A (2013). Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (lipo-). Asian Pac J Cancer Prev, 14, 2131-5. 과학기술학회마을 DOI ScienceOn |
30 | Karaoglu A, Arslan UY, Ozkan M, et al (2009). Efficacy and toxicity of gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant/refractory epithelial ovarian cancer. Asian Pac J Cancer Prev, 10, 63-6. |
31 | Markman M, Webster K, Zanotti K, et al (2003). Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol, 90, 593-6. DOI ScienceOn |
32 | Moore MA, Attasara P, Khuhaprema T, et al (2010). Cancer epidemiology in mainland South-East Asia - past, present and future. Asian Pac J Cancer Prev, 11 Epidemiology Suppl, 67-80. |
33 | Kucukoner M, Isikdogan A, Yaman S, et al (2012). Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the anatolian society of medical oncology. Asian Pac J Cancer Prev, 13, 3973-6. 과학기술학회마을 DOI ScienceOn |